Journal of Gastrointestinal Cancer最新文献

{"title":"Current Status of Gastrectomy for Gastric Cancer in Oldest-old Patients Aged 85 Years or Older.","authors":"Kazuaki Matsui, Yoshiki Kawaguchi, Takahiro Iwai, Yukiko Torizaki, Yoko Adachi, Hirofumi Shimoda, Takehiro Shimada, Yasuhito Sekimoto, Hidejiro Urakami, Shiko Seki","doi":"10.1007/s12029-025-01205-z","DOIUrl":"10.1007/s12029-025-01205-z","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the safety of gastrectomy for gastric cancer in oldest-old patients aged ≥ 85 years.</p><p><strong>Methods: </strong>This study retrospectively analyzed the patients aged ≥ 85 years who diagnosed with gastric cancer between 2008 and 2022. The study patients were divided into three groups: a surgery group, an endoscopic submucosal dissection (ESD) group, and a non-surgery and non-ESD group (n = 64, 57, and 152). Surgical outcomes and 3-year overall and recurrence-free survival (OS and RFS) were investigated.</p><p><strong>Results: </strong>In the surgery group, the study cohort comprised 30 males and 34 females with a median age of 87 years. Distal, proximal, and total gastrectomy (DG, PG, and TG) were performed in 54, 1, and 9 patients, respectively. There were 27, 16, 17, and 4 patients with pStage I, II, III, and IV, respectively. Thirty-day morbidity with Clavien-Dindo grade ≥ 3 and 30-day mortality were 12.5% and 3.1%, respectively. Kaplan-Meier curves for the 3-year OS and RFS demonstrated that survival curves worsened with increasing pStage (p = 0.005 and p < 0.001, respectively). In multivariate analyses for the 3-year OS and RFS, TG and pStage ≥ III were independent risk factors (p = 0.028 and 0.011 in OS, p = 0.021 and 0.001 in RFS). In comparisons of 3-year OSs among the three groups in each cStage, survivals in the surgery group were consistently better than those in the non-surgery and non-ESD group in cStages I to III (p < 0.001, 0.001, and < 0.001 in cStage I, II, and III, respectively).</p><p><strong>Conclusion: </strong>Our findings suggest that the radical gastrectomy for gastric cancer can be performed safely and has a chance to improve survival even in the oldest-old patients aged ≥ 85 years.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"83"},"PeriodicalIF":1.6,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative Prediction of Sarcopenia in Patients Scheduled for Gastric and Colorectal Cancer Surgery.","authors":"Beijia Zhou, Yanjun Song, Chen Chen, Xiaotian Chen, Tingting Tao","doi":"10.1007/s12029-025-01206-y","DOIUrl":"10.1007/s12029-025-01206-y","url":null,"abstract":"<p><strong>Introduction: </strong>Sarcopenia negatively impacts surgical outcomes in gastrointestinal cancer patients, yet practical preoperative screening tools are lacking. The CRP/ALB ratio, a novel biomarker of systemic inflammation and nutritional status, may enhance sarcopenia prediction but remains underexplored in surgical oncology. This study aims to identify the predictors for preoperative sarcopenia prediction in gastric and colorectal cancer patients.</p><p><strong>Methods: </strong>This retrospective study analyzed 145 patients undergoing curative surgery (2019-2021). Sarcopenia was defined by sex-specific CT-measured L3 skeletal muscle index (cutoffs, male ≤ 40.8 cm²/m²; female ≤ 34.9 cm²/m²). Multivariable logistic regression identified predictors, with model performance assessed via ROC analysis and Cohen's Kappa.</p><p><strong>Results: </strong>The cohort (median age 64 years; 73.8% male) comprised 66 gastric (45.5%) and 79 colorectal (54.5%) cancer patients, with 29 (20%) diagnosed with sarcopenia. Sarcopenic patients exhibited a higher NRS 2002 score (P < 0.001), lower PNI score (P < 0.05), and higher CRP/ALB ratio (P < 0.05). Multivariate logistic regression analysis results showed that CRP/ALB ratio (OR = 3.084, 95% CI 1.071-8.882, P = 0.037), age (OR = 1.074, 95% CI 1.021-1.130, P = 0.006), and BMI (OR = 0.667, 95% CI 0.542-0.820, P = 0.000) were associated with the increased risk of sarcopenia. The combined model achieved superior discrimination (AUC = 0.854, 95% CI 0.770-0.937), yielding 75.86% sensitivity and 84.82% specificity at optimal cutoff value - 1.0340, and a Cohen's Kappa coefficient of 0.542 when compared to CT results.</p><p><strong>Conclusion: </strong>The CRP/ALB ratio combined with BMI and age is utilized as a convenient and effective tool for preoperative sarcopenia screening. This model-driven approach provides robust strategies to facilitate preoperative interventions, optimize perioperative care, and enhance long-term oncological outcomes for patients undergoing gastric and colorectal cancer surgery.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"82"},"PeriodicalIF":1.6,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression Levels of Plasma YRNAs in Colorectal Cancer as a Potential Noninvasive Biomarker.","authors":"Eman Tayae, Eman M Osman, Marwa R Tawfik, Neamat Hegazy, Marwa Moaaz, Rasha A Ghazala","doi":"10.1007/s12029-025-01197-w","DOIUrl":"10.1007/s12029-025-01197-w","url":null,"abstract":"<p><strong>Purpose: </strong>Colorectal cancer (CRC) is identified as the second leading cause of cancer-associated deaths worldwide. Therefore, there is ongoing research to discover new potential biomarkers enabling early and noninvasive diagnosis of the disease. YRNAs, a novel class of non-coding RNAs, have been identified as a new player in carcinogenesis and an independent class of clinical biomarkers in various malignancies. Nevertheless, the role of plasma YRNAs in CRC diagnosis and prognosis remains unknown. Therefore, the current study aimed to investigate the clinical significance of plasma YRNAs as a noninvasive biomarker for CRC.</p><p><strong>Methods: </strong>Plasma YRNAs expression was assessed in 50 newly diagnosed CRC patients as well as 50 age- and sex-matched healthy controls using quantitative reverse transcription polymerase chain reaction.</p><p><strong>Results: </strong>All plasma YRNAs expression levels were significantly higher in CRC patients than in controls. A significant correlation was observed between YRNA1 and YRNA3, and between YRNA1 and YRNA4. However, no significant correlation between YRNA1 and YRNA5 was identified. Plasma YRNA1 expression showed the highest diagnostic performance for the detection of CRC using the receiver operating characteristic curve analysis, with a sensitivity of 92% and a specificity of 90%. Nevertheless, when the four YRNAs were combined in a single ROC analysis, sensitivity decreased to 80%, while the specificity remained virtually unchanged. Moreover, significant association was observed between plasma YRNA1 and YRNA3 and tumor stage, grade, lymph node presence, metastasis, and lymphovascular invasion.</p><p><strong>Conclusions: </strong>Plasma YRNA may serve as a potential noninvasive biomarker for the diagnosis and prognosis of CRC with high sensitivity and specificity vs. healthy controls.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"81"},"PeriodicalIF":1.6,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Need for Additional Surgery After Non-Curative Endoscopic Resection in Patients with Remnant Gastric Cancer.","authors":"Tatsunori Minamide, Hiroyuki Ono, Noboru Kawata, Yuki Maeda, Masao Yoshida, Yoichi Yamamoto, Kazunori Takada, Yoshihiro Kishida, Sayo Ito, Kenichiro Imai, Kinichi Hotta, Junya Sato, Hirotoshi Ishiwatari, Hiroyuki Matsubayashi, Akifumi Notsu, Etsuro Bando","doi":"10.1007/s12029-025-01199-8","DOIUrl":"10.1007/s12029-025-01199-8","url":null,"abstract":"<p><strong>Purpose: </strong>Completion total gastrectomy is considered an additional treatment after non-curative endoscopic resection for remnant gastric cancer. However, its high invasiveness remains a concern. This study aimed to assess the necessity of additional surgery after non-curative endoscopic submucosal dissection in patients with remnant gastric cancer.</p><p><strong>Methods: </strong>This study included patients who underwent non-curative endoscopic submucosal dissection for remnant gastric cancer between September 2002 and January 2018. The eCura system was used to stratify the risk of lymph node metastasis into low, intermediate, or high. The overall survival, disease-specific survival, and long-term clinical course were analyzed.</p><p><strong>Results: </strong>Among the 46 patients analyzed, 15 underwent additional completion total gastrectomy, whereas 31 were only followed up. Within a median follow-up period of 62.5 months, the additional surgery and follow-up groups showed 5-year overall survival rates of 79.4% and 76.8% (P = 0.93) and disease-specific survival rates of 92.9% and 92.7% (P = 0.98). A total of 19 low-, 8 intermediate-, and 4 high-risk patients in the follow-up group achieved 5-year disease-specific survival rates of 100%, 100%, and 33.3%. Significant differences were observed in the disease-specific survival between the low- and high-risk patients (P < 0.001) and between the intermediate- and high-risk patients (P = 0.02).</p><p><strong>Conclusion: </strong>Risk stratification using the eCura system allows for individualized treatment decisions, with follow-up being a viable option for low- and intermediate-risk patients and additional surgery recommended for high-risk patients after non-curative endoscopic submucosal dissection for remnant gastric cancer.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"80"},"PeriodicalIF":1.6,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Grade Cystic Mucinous Neoplasm of the Colon: A New Entity? Case Report and Review of Literature.","authors":"Cesar Reategui Sanchez, Roberto Secchi Del Rio, Isabel Dos Santos Marques, Mary R Schwartz, Rachel Schiesser, Eric M Haas","doi":"10.1007/s12029-025-01201-3","DOIUrl":"10.1007/s12029-025-01201-3","url":null,"abstract":"<p><p>Low-grade cystic mucinous neoplasm of the sigmoid colon has never been previously reported and a classification for such a tumor does not currently exist. Here, we present a case of low-grade cystic mucinous neoplasm of the sigmoid colon and discuss the differential diagnosis especially as it relates to clinical management. Our case is a 68-year-old male who presented with anemia and a history of a lower gastrointestinal tract bleed. He denied abdominal pain and weight loss. A colonoscopy was done for further investigation, and he was found to have a 4-cm nonbleeding submucosal mass in the descending colon. Mucosal biopsies were inconclusive. An MRI of the abdomen and pelvis showed a 7.4 × 4.6 cm complex fluid collection involving the mid sigmoid colon with extensive diverticulosis and wall thickening of the sigmoid colon. The differential diagnosis included sequela of diverticulitis vs. neoplasm. Due to the increased risk of obstruction or perforation, a sigmoid resection was recommended. The patient underwent a robotic low anterior resection (LAR). Histological examination demonstrated a cystic mucinous neoplasm filled with acellular mucin and lined by pseudostratified columnar cells with low-grade dysplasia. The tumor involved the muscularis propria and subserosa. Cystic mucinous neoplasm of the colon is not currently recognized among tumors of the colon. Its malignant potential is uncertain. This is the first case report describing a cystic mucinous neoplasm of the sigmoid colon. Recognition of this unusual tumor can help to guide appropriate clinical management and guide further treatment.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"79"},"PeriodicalIF":1.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-Related Differences in Gastric Adenocarcinoma from 2000-2020: A SEER Database Analysis.","authors":"Abdul Qahar Khan Yasinzai, Anwaar Saeed","doi":"10.1007/s12029-025-01168-1","DOIUrl":"10.1007/s12029-025-01168-1","url":null,"abstract":"<p><strong>Introduction: </strong>Gastric cancer (GC) is the 5th most common malignancy worldwide. Adenocarcinoma accounts for 95% of all GC. While most cases of gastric adenocarcinoma (GAC) arise in older age males, a significant proportion of biological disparity exists between different ages. In this study, we aim to compare the demographics and prognostic outcomes of different ages of patients with GAC.</p><p><strong>Methods: </strong>This retrospective study utilized the GAC cases abstracted from the Surveillance, Epidemiology, and End Results Program's 17 registries dataset from 2000 to 2020. Cases were divided into different age group brackets to comparatively explore characteristics of GAC.</p><p><strong>Results: </strong>A total of 103,674 cases were identified. The median age was 69 years, with a significant proportion 39.7% (n = 41,154) falling within the 66-80 age bracket cases. Female proportions were higher in the ≤ 35 years age group 47.2% (n = 960) and ≥ 81 years age group 45.7% (n = 9,695). About 45.1% (n = 916) of ≤ 35 years age group cases were Hispanic, while 60% (n = 12,715) of ≥ 81 years age group cases were non-Hispanic White. Ages between 51-65 and 66-80 years had higher proportions of liver metastasis 17% and 16% than their younger and older peers. Age ≤ 35 years cases are more likely to present at cardia 20.5%. Male gender had the worst survival across all age groups, with the worst in the ≤ 35 age group hazard ratio (H.R) 1.22(1.007 - 1.250 p < 0.001). Black had the worst survival across all ages, with the worst in the ≤ 35 years age group H.R 1.405 (1.164 - 1.696 p < 0.001). When plotted against other races in each age group, Hispanics had poor survival at young ages H.R 1.224 (1.069 - 1.401) and superior survival at older ages, with H.R 0.944 (0.902 - 0.987) in the ≥ 81 age group. Tumors located in the greater curvature and overlapping lesions demonstrated worse prognosis compared to cardia. Conversely, tumors in the pylorus and lesser curvature generally exhibited better prognosis.</p><p><strong>Conclusion: </strong>In the United States GAC predominantly affects older adults, but early-onset cases exhibit aggressive histologies and poor survival, particularly more common in Hispanics. Black individuals face the worst survival outcomes across all age groups. Gender inclination towards males shrinks at the extremes of ages. At different age brackets, the demographics and prognosis changes, necessitating customized interventions.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"78"},"PeriodicalIF":1.6,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Recurrence of Colorectal Liver Metastasis (Number ≤ 5 and Largest Diameter ≤ 3 cm) after Resection or Thermal Ablation: a Multi-center Study of Patterns, Safety, Survival and Risk Factors.","authors":"Yaqing Kong, Xiaoyu Huang, Xiaojing Cao, Fan Tang, Xiang Zhou","doi":"10.1007/s12029-025-01200-4","DOIUrl":"10.1007/s12029-025-01200-4","url":null,"abstract":"<p><strong>Objective: </strong>To compare early recurrence patterns, safety, survival and investigate the clinical risk factors of early recurrence (ER) after liver resection or thermal ablation (TA) for patients with colorectal liver metastases (CRLM) with number ≤ 5 and largest diameter ≤ 3 cm.</p><p><strong>Materials and methods: </strong>This retrospective study included patients with CRLM who underwent liver resection or TA between January 2016 and December 2021 at two hospitals in China. The Kaplan-Meier method and log-rank test were used to assess recurrence-free survival (RFS) and overall survival (OS). Risk factors for ER were analysed using univariate and multivariate Cox regression analyses.</p><p><strong>Results: </strong>303 patients with 632 liver metastases were enrolled. The most common early recurrence pattern was intrahepatic recurrence (IHR) in resection group and TA group. There was no significant difference in 6-month RFS rate (65.81% vs 66.23%) and median OS (P = 0.10) between two groups. Patients without ER had better OS than those with ER (P < 0.05). The incidence of serious complications (P = 0.013), length of hospitalization (P < 0.01), and albumin-bilirubin (ALBI) score (P = 0.038) in TA group were significantly better than resection group. The diameter of liver metastases (HR: 4.89, 95% CI: 1.16-20.60; P = 0.031) and clinical risk score (CRS) (HR: 1.86, 95% CI: 1.06-3.25; P = 0.029) were independent risk factors for ER.</p><p><strong>Conclusion: </strong>For CRLM with largest diameter ≤ 3 cm and number ≤ 5, the efficacy of receiving resection or TA is comparable, and the safety of TA is better. TA may be considered as the first-line local treatment option for patients with CRLM.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"77"},"PeriodicalIF":1.6,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal Cancer Surgery During Summer Holidays: How Safe Is It?","authors":"Fatah Tidadini, Jean-Louis Quesada, Bertrand Trilling, Juliette Fischer, Pierre-Yves Sage, Jean-Luc Faucheron","doi":"10.1007/s12029-025-01198-9","DOIUrl":"https://doi.org/10.1007/s12029-025-01198-9","url":null,"abstract":"","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"76"},"PeriodicalIF":1.6,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy or Targeted Therapy Versus Best Supportive Care for Advanced Gastric Cancer: A Systematic Review and Meta-analysis of Randomized Trials.","authors":"Adriana Meade, Marilina Santero, Olga Savall-Esteve, Javier Bracchiglione, Leire Leache, Anna Selva, Ismael Macias, Paula Cerdà, Xavier Bonfill Cosp","doi":"10.1007/s12029-024-01155-y","DOIUrl":"10.1007/s12029-024-01155-y","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the efficacy and safety of non-chemotherapy anticancer drugs (immunotherapy or targeted therapy) compared to best supportive care (BSC) or placebo for the treatment of advanced gastric cancer (GC).</p><p><strong>Methods: </strong>Systematic review of randomized controlled trials (RCTs) searching (May 2022) MEDLINE, EMBASE, CENTRAL, Epistemonikos, ClinicalTrials.gov, and PROSPERO. Certainty of evidence was evaluated following GRADE.</p><p><strong>Results: </strong>Six RCTs included. Targeted therapies likely result in a slight increase in overall survival (OS) (HR 0.84, 95% CI 0.75, 0.93; moderate certainty) and progression-free survival (PFS) (HR 0.52, 95% CI 0.43, 0.62; moderate certainty). Toxicity had a slightly increased risk (RR 1.19, 95% CI 0.95, 1.48; low certainty). Immunotherapy also showed a likely improvement in PFS (HR 0.60, 95% CI 0.49, 0.73; moderate certainty), while toxicity showed a likely higher risk (RR 2.72, 95% CI 1.24, 5.94; moderate certainty). However, benefits in survival translated to time gains of slightly over a month for OS and less than a month for PFS. No data were reported on performance status (PS), hospital admissions, or quality of life (QoL).</p><p><strong>Conclusions: </strong>Our study suggests some survival benefits with low toxicity from these treatments, but gains are marginal. Uncertainties persist regarding their impact on QoL and outcomes for patients with poor PS. Caution is advised in treatment selection for advanced GC patients, who should actively participate in decision-making. Future research should include diverse patient populations and assess patient-centered outcomes with consistent comparator groups for BSC.</p><p><strong>Trial registration: </strong>The study protocol was registered in OSF ( https://doi.org/10.17605/OSF.IO/7CHX6 ) on 2022-04-01.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"75"},"PeriodicalIF":1.6,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appropriateness of Recommendations for Surveillance Colonoscopy After Polypectomy-A Comparison of Adherence to the 2012 and 2020 USMSTF Guidelines.","authors":"Kacey Idouchi, Mathew J Gregoski, Don C Rockey","doi":"10.1007/s12029-025-01191-2","DOIUrl":"10.1007/s12029-025-01191-2","url":null,"abstract":"<p><strong>Purpose: </strong>The U.S. Multi-Society Task Force (USMSTF) has recommended surveillance intervals that weigh the benefits, harms, and costs of colonoscopy. In 2020, it updated its screening recommendations, and we want to evaluate clinical practice adherence to recommended guideline intervals.</p><p><strong>Methods: </strong>A prospective analysis was performed to examine gastroenterologists' recommendations for screening and surveillance colonoscopy from March 2012 to December 2023. Procedures with unknown histology or unsatisfactory bowel preparation were excluded. We compared polyp morphology, histology, and subsequent recommendations made by gastroenterologists to the USMSTF guidelines.</p><p><strong>Results: </strong>Five hundred thirteen patients and 902 colonoscopies were included. For screening colonoscopies, 200/231 (87%) followed 2012 guidelines, while 75% followed 2020 guidelines. For 1st surveillances, 75% followed 2012 guidelines, and 50% followed 2020 guidelines (p < 0.001). Adherence was also analyzed by year from 2020 to 2023. There were no significant differences in rates for screening colonoscopy and 1st surveillances over this time frame. Since the introduction of the 2020 guidelines for screening colonoscopies, there was a decrease in adherence by 13% for low-risk adenoma (LRA) and an 8% decrease for high-risk adenoma (HRA); there was a 7% increase in adherence for hyperplastic polyps (HP) and an 11% increase in adherence with sessile serrated polyps (SSP). For 1st surveillances, there was a decrease in adherence by 16% for LRA, 11% for HRA, 1% for HP, and 2% for SSP.</p><p><strong>Conclusions: </strong>Since the introduction of the 2020 guidelines, gastroenterologists are recommending colonoscopies more frequently than the guidelines call for. Increasing the evidence behind interval recommendations may increase guideline adherence.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"74"},"PeriodicalIF":1.6,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}